Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS - Disaggregation of net revenues (Details)

v3.21.2
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS - Disaggregation of net revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net $ 19,610 $ 9,447 $ 45,617 $ 30,808
Targadox        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 5,184 7,214 18,110 22,195
Ximino        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 2,864 1,031 6,277 5,854
Exelderm        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 1,366 1,226 4,319 2,913
Accutane        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 3,531   5,672  
Qbrexa        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net 6,636   11,204  
Other branded products        
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Product revenue, net $ 29 $ (24) $ 35 $ (154)